Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients

Inclusion Criteria: * Female patients with stage II or III (cT1cN+ or ≥T2 any cN, cM0) breast cancer. - Planned to receive standard neoadjuvant chemotherapy. * Measurable disease (breast and/or lymph nodes). * WHO performance status 0-2. * Being overweight (BMI: 25-29.9 kg/m2) or obese (BMI: ≥30 kg/m2). * Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l * Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL * Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min * Patients must be accessible for treatment and follow-up Exclusion Criteria: * Serious diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias * Diabetes Mellitus. * Pregnancy or lactating * Any metabolic disorders that may affect gluconeogenesis or adaptation to fasting periods. * Previous malignancy. * Using weight loss medication.